Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Common Equity (2016 - 2025)

iBio (IBIO) has disclosed Common Equity for 15 consecutive years, with $56.6 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 307.05% to $56.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.6 million through Dec 2025, up 307.05% year-over-year, with the annual reading at $14.9 million for FY2025, 30.22% down from the prior year.
  • Common Equity for Q4 2025 was $56.6 million at iBio, up from $56.0 million in the prior quarter.
  • The five-year high for Common Equity was $108.6 million in Q2 2021, with the low at $9.2 million in Q4 2023.
  • Average Common Equity over 5 years is $44.3 million, with a median of $23.1 million recorded in 2024.
  • The sharpest move saw Common Equity surged 2549.23% in 2021, then plummeted 79.22% in 2022.
  • Over 5 years, Common Equity stood at $90.6 million in 2021, then tumbled by 79.22% to $18.8 million in 2022, then tumbled by 51.14% to $9.2 million in 2023, then surged by 51.08% to $13.9 million in 2024, then soared by 307.05% to $56.6 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $56.6 million, $56.0 million, and $14.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.